Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 335-339

  Diaz, John P ^a   Tew, William P ^a   Zivanovic, Oliver ^a   Konner, Jason ^a   Sabbatini, Paul J ^a   dos Santos, Lisa A ^a   Abu Rustum, Nadeem R ^a   Chi, Dennis S ^a   Aghajanian, Carol ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Avastin; Bevacizumab; Gastrointestinal perforations; Ovarian cancer; Ovary; Recurrence

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; APPENDIX PERFORATION; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; LAPAROTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; STOMACH PERFORATION; SURVIVAL TIME; TIME OF DEATH; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; INTESTINAL PERFORATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 75749117463     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.017     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009) 225-249
2. Ho A.G., Beller U., Speyer J.L., Colombo N., Wernz J., and Beckman E.M. A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J. Clin. Oncol. 5 (1987) 1316-1321
3. Lund B., and Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet. Gynecol. 76 (1990) 617-622
4. Alvarez A.A., Krigman H.R., Whitaker R.S., Dodge R.K., and Rodriguez G.C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5 (1999) 587-591
5. Gasparini G., Bonoldi E., Viale G., Verderio P., Boracchi P., Panizzoni G.A., et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer 69 (1996) 205-211
6. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L., and Merino M.J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147 (1995) 33-41
7. Nakanishi Y., Kodama J., Yoshinouchi M., Tokumo K., Kamimura S., Okuda H., et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16 (1997) 256-262
8. Paley P.J., Staskus K.A., Gebhard K., Mohanraj D., Twiggs L.B., Carson L.F., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 (1997) 98-106
9. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
10. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
11. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007) 1539-1544
12. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-Carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006) 2542-2550
13. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676
14. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27 (2009) 4733-4740
15. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007) 5165-5171
16. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (2007) 5180-5186
17. Micha J.P., Goldstein B.H., Rettenmaier M.A., Genesen M., Graham C., Bader K., et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 17 (2007) 771-776
18. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26 (2008) 76-82
19. Rini B.I. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10 (2005) 191-197
20. Monk B.J., Choi D.C., Pugmire G., and Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 96 (2005) 902-905
21. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 (2006) 83-89
22. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl 3 (2005) 25-33
23. Sfakianos G.P., Numnum T.M., Halverson C.B., Panjeti D., Kendrick J.E.t., and Straughn Jr. J.M. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol. Oncol. 114 (2009) 424-426
24. Rose P.G., and Piver M.S. Intestinal perforation secondary to paclitaxel. Gynecol. Oncol. 57 (1995) 270-272
25. Seewaldt V.L., Cain J.M., Goff B.A., Tamimi H., Greer B., and Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol. Oncol. 67 (1997) 137-140
26. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107 (2007) 118-123
27. Badgwell B.D., Camp E.R., Feig B., Wolff R.A., Eng C., Ellis L.M., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann. Oncol. 19 (2008) 577-582
28. Han E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol. Oncol. 105 (2007) 3-6